大剂量美法仑及自体骨髓移植联合或不联合腹部放疗作为完全缓解或微小残留病的卵巢癌巩固治疗手段。
High dose melphalan and ABMT with or without abdominal radiotherapy as consolidation treatment for ovarian carcinoma in complete remission or with microscopic residual disease.
作者信息
Dufour P, Bergerat J P, Liu K L, Bohbot A, Maloisel F, Duclos B, Herbrecht R, Faradji A, Jung J M, Oberling F
机构信息
Dept Onco-Hematology, CHU Hautepierre, Strasbourg.
出版信息
Eur J Gynaecol Oncol. 1991;12(6):457-61.
We initiated in February 1982 a pilot study of high dose melphalan (HDM) and ABMT as consolidation treatment for ovarian carcinoma. Eleven patients entered into this study; 6 patients received HDM and ABMT (group 1), 5 patients received HDM in combination with flash abdominal radiotherapy followed by ABMT (group 2). Two of 6 group 1 patients and 3 of 5 group 2 patients are still alive with NED more than 3 years after ABMT (58+, 72+, 37+, 39+, 43+) and are hopefully cured. Main toxicity was haematological, we have not observed any death related to therapy. HDM and ABMT compared favorably with other consolidation treatments (abdominopelvic radiotherapy or IP chemotherapy) and merits a larger evaluation.
1982年2月，我们启动了一项关于大剂量美法仑（HDM）和自体骨髓移植（ABMT）作为卵巢癌巩固治疗的试点研究。11名患者进入该研究；6名患者接受了HDM和ABMT（第1组），5名患者接受了HDM联合腹部快速放疗，随后进行ABMT（第2组）。第1组6名患者中的2名和第2组5名患者中的3名在ABMT后超过3年仍无疾病证据存活（58岁以上、72岁以上、37岁以上、39岁以上、43岁以上），有望治愈。主要毒性为血液学毒性，我们未观察到任何与治疗相关的死亡。与其他巩固治疗（腹盆腔放疗或腹腔内化疗）相比，HDM和ABMT表现良好，值得进行更大规模的评估。
Zotero 插件